Prokineticins (PROK1/PROK2): Complete Research Profile — Circadian Clock Output, Kallmann Syndrome Genetics, Angiogenesis, and PROKR Biology (2026)

# Prokineticins (PROK1/PROK2): Complete Research Profile — Circadian Clock Output, Kallmann Syndrome Genetics, Angiogenesis, and PROKR Biology (2026)

Among the peptide families whose significance was only fully appreciated through clinical genetics, the prokineticins occupy an important position. Prokineticin 2 (PROK2) — initially identified through its structural similarity to snake venom peptides — turned out to be a critical output signal from the suprachiasmatic nucleus (SCN) circadian clock, a required factor for GnRH neuron migration during development, and a gene whose loss-of-function mutations cause Kallmann syndrome — the combination of anosmia and hypogonadotropic hypogonadism. Prokineticin 1 (PROK1), its structural paralog, emerged as a key placental angiogenic factor and implantation mediator. Together, the prokineticin system represents a convergence of circadian biology, reproductive neuroendocrinology, developmental neuroscience, and vascular biology.

Discovery: From Mamba Venom to Circadian Signaling

Structural Origins and Identification

Prokineticin 1 and 2 were identified in 2001 independently by two research groups through sequence homology with MIT1 (mamba intestinal toxin 1), a cysteine-rich peptide isolated from black mamba (Dendroaspis polylepis) venom. MIT1 and the related colostrum protein 1C6 (from frog skin) defined a new peptide family characterized by:

• •Approximately 80 amino acids
• •Ten cysteine residues forming five intramolecular disulfide bonds in a defined pairing pattern (EGF-like fold)
• •An AVIT domain at the N-terminus (conserved motif required for receptor binding)
• •C-terminal signal anchor region

Li and colleagues (2001) and Schweitz and colleagues simultaneously characterized the two mammalian AVIT-family members:

• •Prokineticin 1 (PROK1): initially named EG-VEGF (endocrine gland-derived VEGF) or AVIT1
• •Prokineticin 2 (PROK2): initially named Bv8 (for its relationship to Bombina variegata peptide 8, a frog skin peptide) or AVIT2

The term "prokineticin" was applied because early characterization showed these peptides stimulate gastrointestinal smooth muscle contraction — a prokinetic action mediated through enteric neuron activation.

Two Receptors: PROKR1 and PROKR2

Two G protein-coupled receptors mediate prokineticin signaling:

PROKR1 (prokineticin receptor 1; previously ZAQ or GPR73a):

• •Higher affinity for PROK1 than PROK2 (though both bind both receptors)
• •Expressed in GI tract, dorsal root ganglia, sensory neurons, kidney, liver
• •Primary receptor for PROK1's peripheral vasoactive and GI actions

PROKR2 (prokineticin receptor 2; previously GPR73b):

• •Comparable affinity for PROK1 and PROK2
• •Expressed in SCN, hypothalamus, olfactory bulb, forebrain, pituitary, peripheral sensory neurons
• •The primary PROK2 receptor in CNS contexts; Kallmann syndrome gene

Both PROKR1 and PROKR2 couple primarily to Gαq/11, activating PLCβ → IP3 → Ca²⁺ mobilization, and to Gαi in some contexts. Both receptors also activate MAPK pathways and promote cell survival and proliferation.

The AVIT Domain

The AVIT domain (named for the conserved amino acids Ala-Val-Ile-Thr at positions 1-4) is required for receptor binding. N-terminal truncations that remove the AVIT domain abolish receptor activity, making the intact N-terminus critical for pharmacological activity — similar to other receptor-binding N-termini like those in GLP-1 or glucagon.

PROK2 in Circadian Rhythm: SCN Output Signal

Circadian Clock Architecture

The suprachiasmatic nucleus (SCN) is the master circadian clock. SCN neurons contain cell-autonomous molecular clocks (CLOCK:BMAL1 → Per/Cry feedback loop) that generate 24-hour rhythms. However, the SCN must communicate this timing information to downstream brain structures and peripheral organs to coordinate physiology with the environment. PROK2 was discovered to be a critical SCN output signal in this communication system.

PROK2 in SCN Circadian Output

Cheng and colleagues published in Cell in 2002 that:

• •PROK2 mRNA expression in the SCN oscillates with a robust circadian rhythm — high during the subjective day, low at night (in both nocturnal and diurnal species)
• •This oscillation is driven by CLOCK:BMAL1 directly transcribing PROK2 — making PROK2 a direct clock-controlled gene (CCG)
• •Intracerebroventricular (ICV) PROK2 injection suppresses locomotor activity in mice — mimicking the behavioral suppression of the "rest phase"
• •PROKR2 is expressed in SCN target areas (sub-paraventricular zone, dorsomedial hypothalamus, hypothalamic areas) — the receiver cells

The model: during the subjective day (rest phase in nocturnal mice), the SCN clock drives PROK2 expression high; PROK2 is secreted from SCN neurons and acts on PROKR2-expressing downstream neurons to suppress activity and promote rest. At night (active phase in mice), PROK2 falls, releasing the brake and permitting behavioral activity.

PROK2 Knockout and Circadian Disruption

Mice lacking PROK2 (Prok2−/−) or PROKR2 (Prokr2−/−) develop severely disrupted circadian rhythms under both LD (light-dark) and DD (constant darkness) conditions:

• •Fragmented locomotor activity patterns
• •Reduced amplitude of circadian behavioral rhythms
• •Accelerated decay of rhythmicity in constant conditions
• •Altered body temperature rhythms
• •Disrupted sleep-wake cycles

Crucially, SCN molecular clock genes (Per1, Per2, Bmal1) continue to oscillate normally in Prok2−/− and Prokr2−/− mice — confirming that the intracellular clock mechanism is intact but its output communication to the rest of the brain is severely impaired. PROK2-PROKR2 is thus positioned not as a clock component but as a clock output relay.

Implications for Circadian Research

The PROK2 finding established that the SCN communicates timing via at least two parallel mechanisms:

1. Neural outputs (direct axonal projections from SCN to targets)

2. Diffusible molecular outputs (PROK2 released into CSF/local tissue to signal circadian phase)

This dual-output model has informed understanding of how circadian timing is maintained even when neural connectivity is disrupted, and how pharmaceutical interventions targeting PROKR2 could potentially modify circadian output independent of the core molecular clock.

PROK2, PROKR2, and Kallmann Syndrome

Kallmann Syndrome Overview

Kallmann syndrome (KS) is a developmental disorder characterized by:

1. Hypogonadotropic hypogonadism (HH): Absent puberty due to deficient GnRH secretion from the hypothalamus

2. Anosmia or severe hyposmia: Absent or impaired sense of smell

The co-occurrence of anosmia and HH reflects a common developmental origin: GnRH neurons originate in the olfactory placode during embryonic development and migrate along olfactory nerve fibers into the hypothalamus. Disruption of this migration causes GnRH deficiency. The associated olfactory bulb hypoplasia causes anosmia.

KS affects approximately 1 in 8,000-10,000 males and 1 in 40,000 females, with multiple causative genes identified.

PROK2 and PROKR2 Mutations in Kallmann Syndrome

Dode and colleagues published in 2006 that heterozygous or homozygous loss-of-function mutations in PROK2 or PROKR2 cause Kallmann syndrome. Key findings:

• •PROK2 and PROKR2 mutations identified in KS patients from multiple unrelated families
• •Both heterozygous (dominant with variable penetrance) and homozygous/compound heterozygous (recessive) mutations cause KS
• •PROKR2 mutations are among the most common genetic causes of KS after KAL1 (anosmin-1)
• •PROK2 mutations tend toward milder phenotypes than PROKR2 mutations, suggesting partial functional redundancy

Developmental Mechanism

Why do PROK2/PROKR2 mutations cause anosmia + GnRH deficiency?

During embryonic development (approximately gestational weeks 5-16 in humans):

1. GnRH neurons originate in the olfactory placode (nasal area)

2. They migrate along vomeronasal/olfactory nerve projections toward the forebrain

3. PROK2 signaling through PROKR2 is required for olfactory bulb morphogenesis (layering of mitral cells, interneuron development) and for guiding GnRH neuron migration into the hypothalamus

4. Without functional PROK2-PROKR2, the olfactory bulb fails to develop normally (hypoplasia) AND GnRH neuron migration is impaired → dual phenotype of anosmia + HH

Mice with Prok2 or Prokr2 knockout confirm this developmental defect: they show olfactory bulb hypoplasia and failure of GnRH neuron migration, mirroring the human KS phenotype.

PROKR2 as a Kallmann Syndrome Diagnostic Gene

Genetic testing of PROKR2 (and PROK2) is now part of routine KS genetic evaluation panels. PROKR2 variants are found in approximately 5-10% of KS patients in European populations. The identification of PROKR2 mutations has practical diagnostic and management implications:

• •Confirms the genetic etiology in affected individuals
• •Allows presymptomatic family member testing
• •Guides reproductive counseling (KS patients can have partial or complete reversal of HH with GnRH or gonadotropin treatment)
• •Informs surveillance for additional features (PROKR2 mutations are associated with variable penetrance and sometimes normosmic IHH without anosmia)

PROK1 in Angiogenesis and Implantation

Endocrine Gland-Derived VEGF

PROK1's discovery as EG-VEGF (endocrine gland-derived vascular endothelial growth factor) by LeCouter and colleagues in 2001 (Science;) highlighted its potent angiogenic activity, specifically in steroidogenic endocrine glands (ovary, testis, adrenal, placenta). Unlike VEGF, which promotes angiogenesis broadly, PROK1/EG-VEGF shows selective angiogenic activity in endocrine tissues, suggesting a role in organ-specific vascular development.

Placental Biology and Implantation

PROK1 is highly expressed in the endometrium and syncytiotrophoblasts of the early placenta, peaking during the implantation window (days 6-10 post-LH surge in humans). Research has established:

• •PROK1 promotes trophoblast invasion into the maternal decidua
• •PROK1 stimulates uterine endometrial cell proliferation, differentiation, and vascularization
• •PROKR1 is expressed on endometrial epithelial and stromal cells
• •PROK1 levels in early pregnancy serum may predict implantation success in some populations

Miscarriage and implantation failure: Reduced PROK1 or PROKR1 expression has been associated with recurrent miscarriage and implantation failure in clinical studies. PROK1 is being explored as a potential biomarker for early pregnancy complications.

Endometriosis: PROK1 is overexpressed in endometriotic lesions and may promote the neovascularization required for ectopic endometrial tissue survival and expansion.

Prokineticins in Pain and Sensory Neurobiology

PROK1 in Inflammatory Pain

PROK1 (as "Bv8" in some literature) plays a major role in inflammatory pain sensitization through PROKR1 and PROKR2 on sensory neurons:

• •Peripheral PROK1 injection produces thermal hyperalgesia and mechanical allodynia
• •PROK1 sensitizes TRPV1 channels on nociceptors
• •PROK1 released by activated mast cells and neutrophils during inflammation acts as a peripheral pain mediator
• •Anti-PROKR1/2 antibodies reduce inflammatory hyperalgesia in rodent models

PROK2 in Visceral Pain

PROK2 in the GI tract (acting through enteric PROKR2) modulates visceral pain. Increased PROK2 in the colon is associated with inflammatory bowel conditions and may contribute to visceral hypersensitivity.

Granulocyte-Derived PROK1 in Cancer Pain

Studies by Shojaei and colleagues demonstrated that tumor-mobilized granulocytes release PROK1 as part of the pro-angiogenic/pro-tumorigenic immune response. This granulocyte-PROK1 axis not only promotes tumor angiogenesis but also contributes to cancer pain sensitization in the tumor microenvironment.

PROK2 in Hematopoiesis

Beyond the CNS, PROK2 promotes granulopoiesis (neutrophil production) from bone marrow progenitors. PROK2 acts on PROKR1-expressing hematopoietic progenitors to:

• •Stimulate granulocyte colony formation
• •Promote neutrophil differentiation and mobilization
• •Contribute to the emergency granulopoiesis response in infection and inflammation

This hematopoietic function has clinical implications: pharmacological PROKR1 agonism has been explored as a potential strategy for treating neutropenia in cancer patients receiving chemotherapy.

Prokineticins in Cancer Research

Angiogenesis: PROK1 and PROK2 promote tumor angiogenesis through VEGF-independent mechanisms. Anti-PROKR1/2 strategies have been explored in preclinical tumor models as anti-angiogenic approaches.

Neuroendocrine tumors: PROK2 is overexpressed in certain neuroendocrine tumors (phaeochromocytoma, paraganglioma). High circulating PROK2 may contribute to paraneoplastic syndromes including polycythemia.

Immunosuppression: PROK2 from tumor-associated macrophages may contribute to immunosuppressive tumor microenvironments by modulating myeloid cell differentiation.

GI Prokinetic Actions

The name "prokineticin" reflects the original observation that both PROK1 and PROK2 stimulate contraction of gastrointestinal smooth muscle through enteric PROKR1/2. Actions include:

• •Accelerated GI transit time
• •Stimulation of gastric and intestinal motility
• •Potent contractile effects on colonic smooth muscle preparations ex vivo

The prokinetic GI properties initially characterized the family before the CNS circadian and developmental roles were discovered.

Research Tools

Current Research Directions (2024-2026)

Kallmann syndrome genomics: Expanding the spectrum of PROK2/PROKR2 variant effects; genotype-phenotype correlations; modifier gene interactions explaining variable penetrance.

Circadian pharmaceuticals: PROKR2 agonists/antagonists as tools to shift circadian phase — potential applications in circadian rhythm sleep disorders and jet lag.

PROK1 as fertility biomarker: Early pregnancy PROK1 serum levels as predictor of miscarriage risk in IVF cycles.

Anti-angiogenic cancer strategies: PROKR1/2 antagonists in combination with VEGF inhibitors for treatment-resistant tumor angiogenesis.

Biased PROKR2 agonism: Developing agonists that maintain circadian output signaling while minimizing pain-sensitizing effects.

Conclusion

The prokineticin family — small, cysteine-rich, evolutionarily ancient peptides — reveals unexpected connections between circadian timekeeping, developmental neuroendocrinology, vascular biology, and pain. PROK2's role as a direct output of the SCN molecular clock positions it as a critical translator of intracellular timing into behavioral and physiological rhythms. PROKR2's requirement for GnRH neuron migration explains one of the commonest genetic causes of Kallmann syndrome, and has made PROKR2 genetic screening routine in clinical evaluation of anosmia + hypogonadotropic hypogonadism. PROK1's endocrine-selective angiogenesis and placental biology add a reproductive vascular dimension to the family's already broad portfolio.

For researchers in circadian biology, reproductive neuroendocrinology, developmental genetics, pain pharmacology, or tumor angiogenesis, prokineticins represent a system whose biological reach extends well beyond its initial characterization as gut prokinetic peptides.

---

References

1. Cheng MY et al. "Prokineticin 2 transmits the behavioral circadian rhythm of the suprachiasmatic nucleus." Nature 2002;417(6887):405-410. PMID: 12024206

5. Pitteloud N et al. "Loss-of-function mutation in the prokineticin 2 gene causes Kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadism." Proc Natl Acad Sci 2007;104(44):17447-17452. PMID: 17959775

7. Belluardo N et al. "Prokineticin 2 is a proalgesic sensory neuropeptide." Pain 2005. [PROK2 pain reference]

8. Shojaei F et al. "Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells and Bv8." Nat Med 2007;13(8):1003-1009. PMID: 17643109

---

This article is intended for research and educational purposes only (RUO). Prokineticins and related research compounds described herein are investigational tools. No compound discussed in this article has been evaluated by regulatory authorities for safety or efficacy in humans for the applications described. This content does not constitute medical advice, clinical guidance, or endorsement of human use.